SEC Tracker
Get the app

Co-Diagnostics CODX

Co-Diagnostics reports Q3 2026 financial results

Co-Diagnostics (CODX) filed an 8-K with the SEC on Nov 10, 2026, 8:02 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Revenue of $0.3 million, up from $0.1 million in Q3 2025
  2. Operating expenses of $6.2 million, down from $7.1 million in Q3 2025
  3. Net loss of $6.3 million, or $1.01 per share, compared to $5.9 million in Q3 2025
  4. Cash and cash equivalents totaled $0.7 million as of September 30, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Co-Diagnostics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.